Lentiviral human ADCY8 sgRNA gene knockout kit

Lentiviral human ADCY8 sgRNA gene knockout kit

Catalog Number:
CGKK547102FEN
Mfr. No.:
HKO-610208
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human ADCY8
          About Target
          Gene symbol: ADCY8
          Synonyms: AC8 ADCY3 HBAC1
          Species: HUMAN
          Gene ID: 114
          Summary: Adenylate cyclase is a membrane bound enzyme that catalyses the formation of cyclic AMP from ATP. The enzymatic activity is under the control of several hormones, and different polypeptides participate in the transduction of the signal from the receptor to the catalytic moiety. Stimulatory or inhibitory receptors (Rs and Ri) interact with G proteins (Gs and Gi) that exhibit GTPase activity and they modulate the activity of the catalytic subunit of the adenylyl cyclase [provided by RefSeq, Jul 2008].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_001115:1:1
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.